Mine is updated since 8/28/2020:
https://www.nbadraft.net/ranking/bigboard/You can see which players have moved up, down, or stayed the same.
I used BR on your list and Bane is #26. No need to overpay in a weak draft. BTW, James Wiseman is #9. On mine, he's #7 and moved up one.
"26. Desmond Bane (TCU, SG, Senior)
Consistent shooting, strong playmaking and a high defensive IQ point to Bane as an NBA fit, even if his lack of speed and explosion limit his creation and finishing. It's easy to picture a supporting rotation player based on his particular versatility and mature approach."
You still want to deal with the team who selects him. They should be willing to trade. Also, you take into account what happens for the Warriors in trade.
B/R has them trading down.
"Trade at 8. Golden State Warriors (via Knicks): Devin Vassell (FSU, SF, Soph)
8 of 13
Golden State Warriors receive: No. 8, No. 27, Dallas Mavericks 2021 first-round pick, Frank Ntilikina
New York Knicks receive: No. 2
Moving down makes sense for the Golden State Warriors if they determine there will be a similarly helpful player at No. 8 as there is at No. 2. They're likely to have trouble approving LaMelo Ball's fit for the lineup and locker room, and drafting a center like James Wiseman at No. 2 just isn't as sensible in today's NBA, particularly for an offense that's run through Stephen Curry, Klay Thompson and Draymond Green.
But a wing like Devin Vassell should have Golden State's attention. The Warriors could use another three-and-D forward, and Vassell has become the most appealing one in the draft after shooting over 40 percent from three in both of his collegiate seasons and consistently making advanced defensive reads, rotations and plays on the ball.
He'd improve the Warriors' athleticism, give them another shot-maker and strengthen their team defense with his IQ and playmaking.
By trading, the Warriors can also squeeze two more first-round picks from the New York Knicks (one via Dallas in 2021), plus another needed perimeter defender in Frank Ntilikina."